Today, AusBiotech Invest brings together investors and selected life sciences company leaders on the Gold Coast for a focused day centred on financing, syndication, cross-border capital and the needs of Australian life sciences companies.
Taking place in Surfers Paradise as part of Australia’s Biggest Week in Biotech, AusBiotech Invest has been redesigned for 2026. Rather than operating as the broad company pitching and networking event of previous years, the forum is now smaller and more focused, creating space for investors to exchange perspectives and engage in deeper financing discussions.
As life sciences companies move through clinical development, manufacturing and commercialisation, their capital requirements increase and financing pathways become more complex. Appropriate capital, credible evidence of progress, experienced leadership and access to domestic and international investors all become increasingly important.
These issues sit at the centre of today’s discussions.
Bringing investors together around financing decisions
AusBiotech Invest brings together perspectives from venture capital, family offices, institutional and private investment, corporate venture and strategic capital, alongside selected company leaders.
The forum is designed to support investor-to-investor discussion, together with focused engagement around the evidence, milestones, risks and capital requirements that shape financing decisions.
Participants bring perspectives across the life sciences investment lifecycle, including scientific and commercial risk, capital allocation, syndication, international expansion and the pathways to value creation.
This creates an opportunity to consider individual financing needs while also examining how Australian companies can better access the capital required to progress through increasingly complex stages of development.
Moving beyond the traditional pitch event
A central feature of the 2026 program is Capital Conversations, a facilitated format involving six selected private life sciences companies.
Rather than conventional company pitches, the discussions use specific company financing needs to explore the evidence, milestones, risks and capital requirements investors consider when deciding whether, and how, to participate.
The format is designed to support candid discussion between investors and company leaders about what creates confidence, where risks remain, what milestones matter most and how companies can position themselves for their next stage of development.
The broader AusBiotech Invest program also focuses on market conditions, domestic syndication, international capital engagement and the experience of building and scaling life sciences companies.
Strengthening Australia’s capital connections
A key focus of AusBiotech’s investment activities is strengthening the connections between Australian life sciences opportunities and the capital required to support their development.
For companies, this means understanding the evidence and milestones required to progress through different stages of growth. For investors, it means building confidence in company leadership, development pathways, financing strategy and the potential for value creation.
Domestic syndication and stronger relationships with global investors are increasingly important as Australian companies seek to finance more complex clinical, regulatory and commercial pathways.
Today’s discussions contribute to that broader effort by creating space for investors to compare perspectives, build relationships and identify where capital can work together more effectively across financing stages and borders.
AusBiotech Invest is one part of a broader week of investment activity across Australia’s Biggest Week in Biotech. Company discovery, one-to-one meetings, Capital Sprint, the Early-Stage Innovation Forum and the dedicated Investment & Global Growth stream continue through the AusBiotech International Conference, providing multiple ways for investors and companies to connect across different stages of growth.
Learn more about AusBiotech Investment and AusBiotech Invest.